anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics, namely a method for preparing and purifying monosialoganglioside GM1. The method for preparing pure monosialoganglioside GM1 in the form of its sodium salt involves (a) GM1 separation from Fucosyl GM1 in a lipid mixture containing monosialoganglioside GM1 as a main ganglioside component by a column ion-exchange chromatography using an eluent comprising potassium or cesium ions, (b) recovery of the dissolved substance from the eluted solution, (c) diafiltration of the aqueous solution of the recovered dissolved substance of the stage (b), (d) addition of sodium salt, and diafiltration of the prepared aqueous solution (d) recovery of GM1 in the form of its sodium salt. The method for purifying monosialoganglioside GM1 from Fucosyl GM1 in the lipid mixture, the column ion-exchange chromatography using the eluent comprising potassium or cesium ions. The preparation of monosialoganglioside GM1 has a purity of 99.0% or more, and contains less than 0.1% of Fucosyl GM1. The method of treating disorders and diseases of the central nervous system and the peripheral nervous system, comprising administering the preparation of monosialoganglioside GM1 to the patient in its effective amount. The use of the preparation of monosialoganglioside GM1 in preparing a pharmaceutical composition.EFFECT: use the above preparation of monosialoganglioside GM1 in treating has the considerable advantages due to reducing side effects.17 cl, 1 ex
PURPOSE:To obtain the subject inhibitor inhibiting the dephosphorylation activity of protein dephosphorylase, useful as an antineoplastic agent, containing, as active ingredient, a specific tetronic acid derivative. CONSTITUTION:Streptomyces sp. 88-682 strain capable of producing a tetronic acid derivative having protein dephosphorylase-inhibitory activity is cultured in a medium of pH 6-10 containing nitrogen source, inorganic salts, vitamins and other nutrients at 10-35 deg.C for 3-14 days under aerobic conditions, and the cultured product is subjected to solvent extraction and isolation and purification by e.g. chromatography to obtain a tetronic acid derivative of the formula. This inhibitor contains the tetronic acid derivative as active ingredient, its dose being pref. 0.1-1000mg/kg adult body weight per time with at least three times a day.
This is a research study to find out what the side effects are of certain drugs that are commonly used for pain and to put people to sleep for surgery. The researchers also want to know how the drug is broken down in the body. Participants will be given these drugs as they are prescribed by their regular doctor. As part of the participant's standard of care, doctors will perform tests, ask questions, review medical information and measure vital signs (heart rate, blood pressure, etc). The researchers will collect information that doctors have already written in the medical records. The research study team will collect blood from participants at certain time points depending on when the participant was first given the drug (up to 5 samples over the course of 10 to 48 hours). Examples of current and upcoming anesthetics and analgesics include, but are not limited to: ketorolac (Toradol), ketamine (Ketalar), oxycodone (OxyContin), and morphine (Kadian, MS Contin).
BACKGROUND: The D-dimer test is a simple test frequently used in routine clinical screening for venous thromboembolism (VTE). The Cancer-VTE Registry was a large-scale, multicenter, prospective, observational study in Japanese patients with cancer. This study aimed to clarify the relationship between D-dimer level at cancer diagnosis (baseline) and the incidence of events during cancer treatment (1-year follow-up period).
METHODS: This was a post hoc sub-analysis of patients from the Cancer-VTE Registry whose D-dimer levels were measured at baseline. The incidence of events during the 1-year follow-up period was evaluated stratified by baseline D-dimer level. Adjusted hazard ratios for D-dimer level and events during the follow-up period were evaluated.
RESULTS: Among the total enrolled patients, baseline D-dimer level was measured in 9020 patients. The mean ± standard deviation baseline D-dimer level was 1.57 ± 3.94 µg/mL. During the follow-up period, the incidence of VTE, cerebral infarction/transient ischemic attack (TIA)/systemic embolic events (SEE), bleeding, and all-cause death increased with increasing baseline D-dimer level. The incidence of all-cause death increased with increasing D-dimer level regardless of cancer stage. The adjusted hazard ratio of all-cause death was 1.03 (95% confidence interval: 1.02-1.03) per 1.0-µg/mL increase in baseline D-dimer level.
CONCLUSIONS: Increases in D-dimer levels were associated with a higher risk of thrombotic events, such as VTE and cerebral infarction/TIA/SEE, during cancer treatment. Furthermore, higher D-dimer levels at cancer diagnosis were associated with a higher mortality rate, regardless of cancer stage.
The invention belongs to the field of biomedicine, and particularly relates to a novel polypeptide with a targeted binding effect on liver cancer cells and application thereof. The amino acid sequences of the polypeptides are respectively: SEQ ID No.1 GLTSMRYHSVIV; SEQ ID NO. 2: GNVAPNSWHKAD, respectively; SEQ ID NO. 3: SAWFLYQAYLRA are provided. The polypeptide and the bioactive fragment and the derivative thereof are used as a medicinal composition and a molecular image probe formed by the targeted polypeptide, a medicament capable of killing tumor cells and an imaging preparation, and the application thereof. The polypeptide of the invention has specific target binding capacity to liver cancer cells, has strong selectivity, and provides a new direction for the clinical early diagnosis of liver cancer and the research and development of targeted drugs.
The invention provides a single-chain antibody targeting TRBV12, a CAR-NK cell and application, wherein the single-chain antibody targeting TRBV12 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions consisting of CDR-H1, CDR-H2 and CDR-H3, and the light chain variable region comprises three complementarity determining regions consisting of CDR-L1, CDR-L2 and CDR-L3; the amino acid sequence of the CDR-H1 is shown as SEQ ID NO. 2, the amino acid sequence of the CDR-H2 is shown as SEQ ID NO. 3, and the amino acid sequence of the CDR-H3 is shown as SEQ ID NO. 4; the amino acid sequence of CDR-L1 is shown as SEQ ID NO. 5, the amino acid sequence of CDR-L2 is shown as SEQ ID NO. 6, and the amino acid sequence of CDR-L3 is shown as SEQ ID NO. 7.
Hypertension relieving pills of radix cyathulae are a new technology which is invented by the long-time search and research of an applicant and also by long-time clinical practice and is used for treating hypertension. The problem that the disease of the hypertension can not be radically treated by Western medicines and other medicines for a long time is overcome by the applicant. The formula comprises the following components: 30g of the radix cyathulae, 30g of radix salviae miltiorrhizae, 24g of xiqiancao, 10g of peach kernel, 12g of safflower, 15g of semen cassiae torae and 6g of stir-fried rhubarb. The formula has the pharmacological actions of removing heat from the liver, reducing pathogenic fire, detoxicating, eliminating blood stasis, promoting blood circulation, restoring menstrual flow, eradicating blood stasis, dissipating the blood stasis, eliminating the blood stasis, alleviating pain, removing heat from the liver, tonifying the kidney, soothing the nerves and lowering the blood pressure. After the hypertension relieving pills of the radix cyathulae are taken by a patient, the ailment is relieved, and the blood pressure can also be lowered to a normal state. After administration, no adverse phenomenon exists, no toxic or side effect exists, and a cured patient does not relapse generally. By proving through healing 10 cases, the hypertension relieving pills of the radix cyathulae are a uniquely effective new technology which is invented currently and is used for treating the symptom of the hypertension.
The etiological agent responsible for non-A, non-B hepatitis has been identified and termed hepatitis C virus (HCV). The HCV genome is a linear, positive-stranded RNA molecule with a length of approximately 9,400 nucleotides. With the exception of rather short untranslated regions at the termini, the genome consists of one large, uninterrupted, open reading frame encoding a polyprotein of approximately 3,000 amino acids. This polyprotein has been shown to be cleaved co-translationally into individual viral structural and non-structural (NS) regions. The structural protein region is further divided into capsid (Core) and envelope (E1 and E2) regions. The NS regions are divided into NS-1 to NS-5. The present invention is directed toward peptides derived from the HCV NS4 region that contain immunologically important epitopes. A series of biotinylated peptides were prepared by solid phase peptide synthesis and these peptides have proven useful for the detection of HCV-specific antisera.
Subjects in the "Cognitive Behavioral Treatment" Arm will undergo 8-10 weeks of remote cognitive behavioral therapy. Subjects will complete modules on their phones and will be monitored by study coordinators for support and treatment completion.
BACKGROUND: Obesity is characterized by excessive fat accumulation, which is related with abnormal pluripotency of mesenchymal stem cells (MSCs). Recently, there is growing evidence that the disorder of maternal vitamin D (VD) intake is a well-known risk factor for long-term adverse health outcomes to their offspring. Otherwise, less is known of its repercussion and underlying mechanisms on the different differentiation potential of MSCs.
METHODS: Four-week-old female C57BL/6J mice were fed with different VD reproductive diets throughout the whole pregnancy and lactation. The characteristics of BMSCs from their seven-day male offspring, VDR knockdown establishment of HuMSCs and HuMSCs under the different VD interventions in vitro were confirmed by flow cytometry, RT-PCR, and immunofluorescence. The roles of VD on their mitochondrial dysfunction and differentiation potential were also investigated. Then their remaining weaned male pups were induced by administrating high-fat-diet (HFD) for 16 weeks and normal fat diet was simultaneously as controls. Their lipid accumulation and adipocytes hypertrophy were determined by histological staining and related gene expressions.
RESULTS: Herein, it was proved that imbalance of early-life VD intake could significantly aggravate the occurrence of obesity by inducing the adipogenesis through affecting the VD metabolism and related metabolites (P < 0.05). Moreover, abnormally maternal VD intake might be involved on the disorders of differentiation potential to inhibit the maintenance of MSCs stemness through increasing the productions of ROS, which was accompanied by impairing the expression of related genes on the adipo-osteogenic differentiation (P < 0.05). Moreover, it was along with increasing potential of adipogenic differentiation of MSCs as higher ROS in the state of VD deficiency, while excessive maternal VD status could conversely enhance the osteogenic differentiation with slightly lower ROS (P < 0.05). Furthermore, the underlying mechanisms might be involved on the mitochondria dysfunctional, especially the mitophagy, by activating the LC3b, P62 and etc. using in vivo and in vitro studies (P < 0.05).
CONCLUSION: These findings demonstrated that imbalance of early-life VD intake could target ROS-mediated crosstalk between mitochondrial dysfunction and differentiation potential of MSCs, which was significantly associated with the later obesity. Obviously, our results could open up an attractive modality for the benefits of suitable VD intake during the pregnancy and lactation.
Up to 56 healthy male and female adult subjects will be enrolled into one of 7 Dose Cohorts (Dose Cohorts 1 to 7; n = 8 per cohort). Cohort 7 (n = 8) is a Food Effect Cohort and subjects will receive a single dose of epetraborole or placebo in a Fasted state (Period 1) followed by a second dose of the same Investigational Product (IP) in a Fed state (Period 2) after a washout period of at least 7 days (+3 days). The dose of IP to be administered in Cohort 7 will be determined based on the Safety Monitoring Group recommendation following evaluation of safety and available PK data (at least 14 days) in Cohort 1 through Cohort 6. Up to 16 additional subjects may be included for the purposes of cohort expansion or to explore a dose intermediate to previously evaluated doses.

Subjects in each Dose Cohort (n=8) will be randomized 3:1 to receive epetraborole (n=6) or matching placebo (n=2) and will receive oral doses of epetraborole or placebo. Investigational product will be administered with approximately 240 mL (8 fluid ounces) of non-carbonated water to each subject following an overnight fast of at least 8 hours, except for Period 2 (Fed) of Cohort 7. Subjects will be required to fast for a minimum of 2 hours following administration of IP.
BACKGROUND: Sarcopenia, a hallmark of age-related muscle function decline, significantly impacts elderly physical health. This systematic review aimed to investigate the impact of gut microbiota on sarcopenia.
METHODS: Publications up to September 24, 2023 were scrutinized on four databases - PubMed, Web of Science, Cochrane Library, and Embase - using relevant keywords. Non-English papers were disregarded. Data regarding gut microbiota alterations in sarcopenic patients/animal models were collected and examined.
RESULTS: Thirteen human and eight animal studies were included. The human studies involved 732 sarcopenic or potentially sarcopenic participants (aged 57-98) and 2559 healthy subjects (aged 54-84). Animal studies encompassed five mouse and three rat experiments. Results indicated an increase in opportunistic pathogens like Enterobacteriaceae, accompanied by changes in several metabolite-related organisms. For example, Bacteroides fluxus related to horse uric acid metabolism exhibited increased abundance. However, Roseburia, Faecalibacterium, Faecalibacterium prausnitzii, Eubacterium retale, Akkermansiaa, Coprococcus, Clostridium_XIVa, Ruminococcaceae, Bacteroides, Clostridium, Eubacterium involved in urolithin A production, and Lactobacillus, Bacteroides, and Clostridium associated with bile acid metabolism displayed decreased abundance.
CONCLUSIONS: Age-related sarcopenia and gut microbiota alterations are intricately linked. Short-chain fatty acid metabolism, urolithin A, and bile acid production may be pivotal factors in the gut-muscle axis pathway. Supplementation with beneficial metabolite-associated microorganisms could enhance muscle function, mitigate muscle atrophy, and decelerate sarcopenia progression.
This is the first clinical trial of the VRC-HIVMAB060-00-AB (VRC01) monoclonal antibody. VRC01 is a broadly neutralizing antibody directed against HIV. This is a dose-escalation study to examine safety, tolerability, dose and pharmacokinetics of VRC01. The hypothesis is that VRC 01 will be safe for administration to HIV-1- infected adults by the intravenous (IV) and subcutaneous (SC) routes and will not elicit hypersensitivity reactions. Samples will be collected to learn if VRC01 is detectable in mucosal secretions and blood of participants and how long VRC01 can be detected in the blood after it is given.

Up to 30 HIV-1 infected adults will be enrolled. Adult 18-60 years old will participate in the dose escalation part of the study. There are 4 dose escalation groups for IV administration; the doses are 1 mg/kg, 5 mg/kg, 20 mg/kg and 40 mg/kg. There is 1 group for SC administration at 5 mg/kg. Each dose escalation group is expected to include at least 3 participants. Each participant during the dose escalation part of the study will receive two infusions of VRC01 with about 1 month between doses, with infusions administered in an inpatient unit and an overnight stay at the NIH Clinical Center required. No more than one subject per day per group will receive a first infusion of the VRC01 product by the IV route and no more than one subject per week will receive a first infusion of the product by the SC route. Study participation lasts for 24 weeks for participants who receive two doses. After the dose escalation is completed, about 10 HIV-infected adults, ages 18-70 years old, with detectable viral load will be enrolled to receive one dose of VRC01 at 40 mg/kg IV with follow-up for 12 weeks. Participant health and effect on CD4 count and HIV viral load will be monitored. Samples will be collected and stored for research purposes.
The cyclic FMD diet consists of a 5 day regimen: day 1 diet of the diet supplies \~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
NEW MATERIAL:An inhibitory substance for synthesis of T cells having the following properties; Elementary analysis; C, H, O, N and S. Molecular weight; 1,000 daltons. Thermal stability; Stable at -20 deg.C for several months, at 56 deg.C for 30min-1hr and at 100 deg.C for 30min. Weakly basic. pH stability; Stable at 3.5- 10.0pH. Ultraviolet absorption; Maximum absorption at 210-220nm. Color reaction; Positive to ninhydrin. Solubility; Readily soluble in water, ethanol and methanol. Colorless on dissolving in the above-mentioned solvents. USE:An inhibitory substance for synthesis of T cell DNA useful for treating autoimmune diseases. PREPARATION:A fibroblastic cell or lymphocyte of an animal, e.g. a mouse or rat or an insect, e.g. silkworm, is cultivated in a culture medium, e.g. Phorbol myristate, by the liquid culture method with aeration. After cell cultivation, the cell is removed by centrifugation, and the culture supernatant liquid is recovered. Saturated ammonium sulfate is then added thereto to salt out the supernatant liquid. The salted out precipitate obtained by centrifugation is then dissolved in physiological saline solution and subjected to the column chromatrography and eluted with saline solution to give the aimed inhibitory substance for synthesis of T cell from the fraction containing low-molecular weight substances.
The invention relates to a biocompatible composition. The composition comprises a porous material of a bioresorbable organic polymer with hydroxyl- and/or carboxylic acid groups, and a bioactive material. According to one alternative, said bioactive material is distributed within said porous material. In this case said bioactive material can be present i) as particles embedded in said porous material, wherein said porous material is a spongy cellulose material, and/or ii) as a Si-gel derived from a solution containing a silicon compound, said solution having been brought into contact with the porous material. According to another alternative, said porous material is a spongy cellulose material and shaped to a reservoir encompassing particles of or a gel of said bioactive material. Methods for its preparation as well as to uses thereof are also included in the invention.
Psoriasis is a chronic inflammatory skin disease affecting 1 to 3% of the French population. Moderate to severe psoriasis has a significant impact on quality of life. Psoriasis is associated with an increased risk of depression, social isolation, unemployment. In addition, it has recently be shown that patients with moderate to severe psoriasis have an increased incidence of cardiovascular risk factors such as hypertension, overweight, hyperlipidemia and exposure to tobacco and alcohol. These so-called comorbidites may have a negative impact on psoriasis management. They also may account for the reduced life expectancy reported in patients with severe psoriasis. Therapeutic education is a structured process whose objective is to help patients to acquire or to maintain competencies that are required to live with a chronic disease. Therapeutic education is an important process to be integrated into the therapeutic strategy. It has to take into account co-morbidities, social and psychological context and its priorities need to be defined with the patient.
Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
Sessile benthic organisms like oysters inhabit the intertidal zone, subject to alternating hypoxia and reoxygenation (H/R) episodes during tidal movements, impacting respiratory chain activities and metabolome compositions. We investigated the effects of constant severe hypoxia (90 min at ~ 0% O2 ) followed by 10 min reoxygenation, and cyclic hypoxia (5 cycles of 15 min at ~ 0% O2 and 10 min reoxygenation) on isolated mitochondria from the gill and the digestive gland of Crassostrea gigas respiring on pyruvate, palmitate, or succinate. Constant hypoxia suppressed oxidative phosphorylation (OXPHOS), particularly during Complex I-linked substrates oxidation. It had no effect on mitochondrial reactive oxygen species (ROS) efflux but increased fractional electron leak (FEL). In mitochondria oxidizing Complex I substrates, exposure to cyclic hypoxia prompted a significant drop after the first H/R cycle. In contrast, succinate-driven respiration only showed significant decline after the third to fifth H/R cycle. ROS efflux saw little change during cyclic hypoxia regardless of the oxidized substrate, but Complex I-driven FEL tended to increase with each subsequent H/R cycle. These observations suggest that succinate may serve as a beneficial stress fuel under H/R conditions, aiding in the post-hypoxic recovery of oysters by reducing oxidative stress and facilitating rapid ATP re-synthesis. The impacts of constant and cyclic hypoxia of similar duration on mitochondrial respiration and oxidative lesions in the proteins were comparable indicating that the mitochondrial damage is mostly determined by the lack of oxygen and mitochondrial depolarization. The ROS efflux in the mitochondria of oysters was minimally affected by oxygen fluctuations indicating that tight regulation of ROS production may contribute to robust mitochondrial phenotype of oysters and protect against H/R induced stress.
Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve.